Ovid Therapeutics (OVID) Assets Average (2017 - 2026)

Ovid Therapeutics' Assets Average history runs 10 years deep, the most recent figure standing at $188.3 million for Q1 2026.

• Quarterly Assets Average rose 116.64% year-over-year to $188.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.3 million (up 116.64% YoY) and the FY2025 annual result came in at $121.6 million, up 2.92% from the prior year.
• Assets Average was $188.3 million for Q1 2026 at Ovid Therapeutics, up from $107.4 million in the prior quarter.
• Across five years, Assets Average topped out at $192.8 million in Q1 2022 and bottomed at $70.6 million in Q3 2025.
• A 5-year average of $133.3 million and a median of $134.5 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average sank 36.94% — and 2026, when it jumped 116.64%.
• Ovid Therapeutics' Assets Average stood at $160.1 million in 2022, then slipped by 16.0% to $134.5 million in 2023, then dropped by 27.59% to $97.4 million in 2024, then climbed by 10.25% to $107.4 million in 2025, then surged by 75.32% to $188.3 million in 2026.
• Business Quant data shows OVID's Assets Average at $188.3 million in Q1 2026, $107.4 million in Q4 2025, and $70.6 million in Q3 2025.